New Industry Group to Ask FDA to Reconsider IVDMIA Plans; Says New Oversight Could 'Impede' Innovation | GenomeWeb
NEW YORK (GenomeWeb News) — A newly formed group comprising genomic, proteomic, and molecular diagnostic companies and investors today said they plan to ask the US Food and Drug Administration to consider altering its plan to regulate certain diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.